Evidence map›Paper›PMID 31248666›Full record

ArticleLancet (London, England)2019

Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Maigeng Zhou, Haidong Wang, Xinying Zeng, Peng Yin, Jun Zhu, Wanqing Chen, Xiaohong Li, Lijun Wang, Limin Wang, Yunning Liu and 18 more

Erratum issued 16 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Lancet (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 16 registered trials, which are not on this map. Cited by 2,018 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2,018citing papers in PubMed, 6 pooled it
693.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05976893 phase4unknown statusstarted 2023, after this paper: background citation

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Ran2023Enrolled620Registered outcomes5Posted comparisons0ConditionsASCVD, Atherosclerotic Cardiovascular Disease, Cancer, Proprotein Convertase Subtilisin/Kexin Type 9 InhibitorArmsEvolocumab, Statin
Open the trial in the graph
NCT04172376 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Stereotactic Operation Integrating With Thrombolysis in Basal Ganglion Hemorrhage Evacuation II (SOITBE II)

TypeinterventionalSponsorSecond Affiliated Hospital, Zhejiang University, School of MedicineRan2021 to 2023Enrolled400ConditionsBasal Ganglia HemorrhageArmsMinimally invasive puncture aspiration plus rt-PA, Conservative medical treatment
NCT04521153 phase2 / phase3active not recruitingnot on this mapstarted 2021, after this paper: background citation

Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma:a Randomized, Open-label, Parallel, Multicenter Trial

TypeinterventionalSponsorShanghai Zhongshan HospitalRan2021 to 2026Enrolled294ConditionsHepatocellular Carcinoma, Immunotherapy, Molecular Targeted TherapyArmsCamrelizumab, Apatinib Mesylate, Radical surgery
NCT04948749 narecruitingnot on this mapstarted 2021, after this paper: background citation

Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE)

TypeinterventionalSponsorBeijing Tiantan HospitalRan2021 to 2027Enrolled358ConditionsICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis, Drug-eluting Stent, StrokeArmsDrug Eluting Stent implantation, Aggressive medical treatment, Risk factor management, Standard medical treatment
NCT05094869 unknown statusnot on this mapstarted 2021, after this paper: background citation

Prevention of HCC Using Mobile Phone Applications: A Disease Management Project Based on CR-HepB Platform

TypeobservationalSponsorBeijing Friendship HospitalRan2021 to 2023Enrolled8,000ConditionsLiver Cirrhosis, Hepatitis BArmsUse of mobile health application, Online interaction, Self follow-up reminders, Intelligent follow-up reminders
NCT05557656 unknown statusnot on this mapstarted 2023, after this paper: background citation

A Real World Study of Regogfinib in the Treatment of Advanced Hepatocellular Carcinoma

TypeobservationalSponsorZhongda HospitalRan2023 to 2023Enrolled800ConditionsHepatocellular CarcinomaArmsRegorafenib 40 MG
NCT05585255 unknown statusnot on this mapstarted 2022, after this paper: background citation

Clinical Significance, Mechanism of Action, and New Targeted Drug Research of DKK2 Protein in Cerebral Ischemia-reperfusion Injury

Typeobservational_patient_registrySponsorNanfang Hospital, Southern Medical UniversityRan2022 to 2024Enrolled108ConditionsIschemic Stroke, Acute, Ischemia-reperfusion Injury, Cerebral EdemaArmsenzyme-linked immunosorbent assay(ELISA)
NCT05719883 nacompletednot on this mapstarted 2023, after this paper: background citation

A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of the Maurora® Sirolimus-Eluting Stent Versus the Apollo Stent in Intracranial Atherosclerotic Stenosis(Maurora ICAS Trial)

TypeinterventionalSponsorBeijing Tiantan HospitalRan2023 to 2025Enrolled156ConditionsIntracranial Arteriosclerosis, Stroke (CVA) or TIAArmsMaurora® Sirolimus Eluting Stent System, APOLLO™ Intracranial Stent System
NCT06143579 phase2not yet recruitingnot on this mapstarted 2023, after this paper: background citation

FOLFOX-Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma:A Single-arm, Open-label, Single Center, Phase II Trial

TypeinterventionalSponsorSun Yat-sen UniversityRan2023 to 2026Enrolled48ConditionsPotentially Resectable Hepatocellular CarcinomaArmsFOLFOX-HAIC+Lenvatinib+Envolizumab
NCT06272656 unknown statusnot on this mapstarted 2024, after this paper: background citation

Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma

TypeobservationalSponsorHebei Medical University Third HospitalRan2024 to 2025Enrolled200ConditionsHepatocellular Carcinoma
NCT06761183 early_phase1not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Safety and Preliminary Efficacy of NXL-001 in Patients with Ischemic Stroke

TypeinterventionalSponsorBeijing Tiantan HospitalRan2025 to 2026Enrolled9ConditionsIschemic StrokeArmsintracerebral stereotactic injection of NXL-001
NCT06918145 naenrolling by invitationnot on this mapstarted 2025, after this paper: background citation

Clinical Study on the Safety, Efficacy, and Mechanisms of Lymphaticovenous Anastomosis (LVA) for the Treatment of Alzheimer's Disease (AD)

TypeinterventionalSponsorPeking University Third HospitalRan2025 to 2030Enrolled80ConditionsAlzheimer&Amp, #39, s Disease (AD)ArmsLymphaticovenous Anastomosis
NCT06958666 narecruitingnot on this mapstarted 2025, after this paper: background citation

Effectiveness of DITM Versus IMT in COPD Patients With High Symptom Burden and High Risk of Acute Exacerbation: A Randomized Controlled Study

TypeinterventionalSponsorSir Run Run Shaw HospitalRan2025 to 2028Enrolled410ConditionsCOPD (Chronic Obstructive Pulmonary Disease)ArmsDigital Inhaled Therapy Management, Inspiratory Muscle Training
NCT06970054 naactive not recruitingnot on this mapstarted 2026, after this paper: background citation

Home Oscillatory Positive Expiratory Pressure Combined With Aerobic Exercise in Moderate to Severe COPD Patients: A Multicenter, Randomized Controlled Study

TypeinterventionalSponsorSir Run Run Shaw HospitalRan2026 to 2029Enrolled312ConditionsCOPD, AECOPDArmsOPEP, Aerobic Exercise
NCT07154355 narecruitingnot on this mapstarted 2025, after this paper: background citation

Clinical Study Protocol on the Impact of Community-Based Exercise Training on the Exercise Capacity of Patients With Reduced Cardiovascular and Pulmonary Function

TypeinterventionalSponsorGuangdong Provincial People's HospitalRan2025 to 2030Enrolled200ConditionsCoronary Heart Disease (CHD), Heart Failure, Cardiomyopathy, COPDArmscommunity-based exercise training
NCT07754942 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Local-to-Systemic Inflammatory Biomarker Gradients and 90-Day Functional Outcomes in Patients With Acute Ischemic Stroke Due to Anterior Circulation Large Vessel Occlusion Undergoing Mechanical Thrombectomy: A Prospective Observational Cohort Study

TypeobservationalSponsorZhongshan Hospital Xiamen UniversityRan2026 to 2029Enrolled50ConditionsAcute Ischemic Stroke, Large Vessel OcclusionArmsProspective Mechanical Thrombectomy Cohort
3 · Its place in the literature

Who cites it

2,018 citing papers in PubMed, 6 syntheses or guidelines pooled it, 3,656 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Anxiety disorders in China and G20 countries: A comparative burden study.The Journal of international medical research · 2026
    Article
  18. Article
  19. Article
  20. Article

1,958 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 6 institutions in 2 countries.

Maigeng ZhouNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Haidong WangInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Xinying ZengNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Peng YinNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Jun ZhuNational Office for Maternal and Child Health Surveillance, Chengdu, China.
Wanqing ChenNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Xiaohong LiNational Office for Maternal and Child Health Surveillance, Chengdu, China.
Lijun WangNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Limin WangNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yunning LiuNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Jiangmei LiuNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Mei ZhangNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Jinlei QiNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Shicheng YuChinese Center for Disease Control and Prevention, Beijing, China.
Ashkan AfshinInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Emmanuela GakidouInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Scott GlennInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Varsha Sarah KrishInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Molly Katherine Miller-PetrieInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
W Cliff Mountjoy-VenningInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Erin C MullanyInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Sofia Boston RedfordInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Hongyan LiuChina Population and Development Research Center, Beijing, China.
Mohsen NaghaviInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Simon I HayInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
Linhong WangNational Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Christopher J L MurrayInstitute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. Electronic address: cjlm@uw.edu.
Xiaofeng LiangChinese Center for Disease Control and Prevention, Beijing, China. Electronic address: liangxf@chinacdc.cn.
National Center for Chronic and Noncommunicable Disease Control and Prevention · CNInstitute for Health Metrics and Evaluation · USUniversity of Washington · USChinese Center For Disease Control and Prevention · CNChina Population and Development Research Center · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPublic health is a priority for the Chinese Government. Evidence-based decision making for health at the province level in China, which is home to a fifth of the global population, is of paramount importance. This analysis uses data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 to help inform decision making and monitor progress on health at the province level.

methodsWe used the methods in GBD 2017 to analyse health patterns in the 34 province-level administrative units in China from 1990 to 2017. We estimated all-cause and cause-specific mortality, years of life lost (YLLs), years lived with disability (YLDs), disability-adjusted life-years (DALYs), summary exposure values (SEVs), and attributable risk. We compared the observed results with expected values estimated based on the Socio-demographic Index (SDI).

findingsStroke and ischaemic heart disease were the leading causes of death and DALYs at the national level in China in 2017. Age-standardised DALYs per 100 000 population decreased by 33·1% (95% uncertainty interval [UI] 29·8 to 37·4) for stroke and increased by 4·6% (-3·3 to 10·7) for ischaemic heart disease from 1990 to 2017. Age-standardised stroke, ischaemic heart disease, lung cancer, chronic obstructive pulmonary disease, and liver cancer were the five leading causes of YLLs in 2017. Musculoskeletal disorders, mental health disorders, and sense organ diseases were the three leading causes of YLDs in 2017, and high systolic blood pressure, smoking, high-sodium diet, and ambient particulate matter pollution were among the leading four risk factors contributing to deaths and DALYs. All provinces had higher than expected DALYs per 100 000 population for liver cancer, with the observed to expected ratio ranging from 2·04 to 6·88. The all-cause age-standardised DALYs per 100 000 population were lower than expected in all provinces in 2017, and among the top 20 level 3 causes were lower than expected for ischaemic heart disease, Alzheimer's disease, headache disorder, and low back pain. The largest percentage change at the national level in age-standardised SEVs among the top ten leading risk factors was in high body-mass index (185%, 95% UI 113·1 to 247·7]), followed by ambient particulate matter pollution (88·5%, 66·4 to 116·4).

interpretationChina has made substantial progress in reducing the burden of many diseases and disabilities. Strategies targeting chronic diseases, particularly in the elderly, should be prioritised in the expanding Chinese health-care system.

fundingChina National Key Research and Development Program and Bill & Melinda Gates Foundation.

Indexed as

Global Burden of DiseaseMorbidityMortalityAdolescentAdultAgedAged, 80 and overAir PollutionCause of DeathChildChild, PreschoolChinaDietFemaleHumansHypertensionParticulate Matter

Identifiers

PMID31248666
PMCPMC6891889
OpenAlexW2953282350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

and 10 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.